CAS 189691-06-3
:PT-141
- Bremelanotide
- Brmelanotice
- Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH
- (3S,6S,9R,12S,23S)-15-[(N-acetyl-L-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxylic acid
- Brmelanotide
- Pt141
- Bromelanotide
(3S,6S,9R,12S,15S,23S)-9-benzyl-6-(3-carbamimidamidopropyl)-15-[(2S)-2-acetamidohexanamido]-12-[(1H-imidazol-4-yl)methyl]-3-[(1H-indol-3-yl)methyl]-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxylic acid
CAS :Formule :C50H68N14O10Degré de pureté :≥97%Masse moléculaire :1025.1627Bremelanotide
CAS :Bremelanotide is a synthetic peptide analog of alpha-MSH and is an agonist at melanocortin receptors including the MC3R and MC4R.Formule :C50H68N14O10Degré de pureté :98%Couleur et forme :White PowderMasse moléculaire :1025.16Bremelanotide Acetate Hydrate
CAS :Produit contrôléStability Hygroscopic
Applications Bremelanotide is a melanocortin receptor agonist shown to improve female sexual function in females suffering from sexual dysfunction.
References Safarinejad, M. et al.: J. Sex. Med., 50, 887 (2008); Pfaus, J. et al.: J. Sex. Med., 4, 269 (2007);Formule :C52H74N14O13Couleur et forme :NeatMasse moléculaire :1103.23Bremelanotide
CAS :Bremelanotide is a synthetic cyclic peptide, classified as a melanocortin receptor agonist. It is derived from the analogs of the alpha-melanocyte-stimulating hormone (α-MSH), with its origins in melanocortin system research. This product acts primarily through the activation of melanocortin 4 receptor (MC4R) pathways in the central nervous system.Bremelanotide exerts its physiological effects by stimulating these receptors, leading to increased neural signals related to sexual arousal and desire. The melanocortin receptors, especially MC4R, play a significant role in modulating various neural networks involved in sexual function.This compound is utilized primarily for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. By enhancing sexual desire and arousal, Bremelanotide provides a therapeutic option for individuals experiencing clinically significant distress related to low sexual desire. Its application in clinical settings highlights the potential of melanocortin pathways as therapeutic targets beyond their established roles in pigmentary and energy balance modulation.
Formule :C50H68N14O10Degré de pureté :Min. 95%Couleur et forme :White PowderMasse moléculaire :1,025.16 g/mol





